1 |
Hua C, Liu X, Liang L, Wang L, Zhong J. Targeting the microRNA-34a as a Novel Therapeutic Strategy for Cardiovascular Diseases. Front Cardiovasc Med 2022;8:784044. [DOI: 10.3389/fcvm.2021.784044] [Reference Citation Analysis]
|
2 |
Zalewski DP, Ruszel KP, Stępniewski A, Gałkowski D, Feldo M, Kocki J, Bogucka-kocka A. Application of OpenArray RT-qPCR for identification of microRNA expression signatures of lower extremity artery disease. J Appl Genetics. [DOI: 10.1007/s13353-022-00692-1] [Reference Citation Analysis]
|
3 |
Li H, Chen M, Feng Q, Zhu L, Bai Z, Wang B, Guo Z, Hou A, Li H. MicroRNA-34a in coronary heart disease: Correlation with disease risk, blood lipid, stenosis degree, inflammatory cytokines, and cell adhesion molecules. J Clin Lab Anal 2021;:e24138. [PMID: 34861059 DOI: 10.1002/jcla.24138] [Reference Citation Analysis]
|
4 |
Stafim da Cunha R, Gregório PC, Maciel RAP, Favretto G, Franco CRC, Gonçalves JP, de Azevedo MLV, Pecoits-Filho R, Stinghen AEM. Uremic toxins activate CREB/ATF1 in endothelial cells related to chronic kidney disease. Biochem Pharmacol 2022;198:114984. [PMID: 35245485 DOI: 10.1016/j.bcp.2022.114984] [Reference Citation Analysis]
|
5 |
Kwiatkowska I, Hermanowicz JM, Mysliwiec M, Pawlak D. Oxidative Storm Induced by Tryptophan Metabolites: Missing Link between Atherosclerosis and Chronic Kidney Disease. Oxid Med Cell Longev 2020;2020:6656033. [PMID: 33456671 DOI: 10.1155/2020/6656033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|